Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIS Mites sublingual tablets dose-finding study in house dust mite allergic rhinoconjunctivitis
2017-005079-21Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- May 2018
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LAIS Mites Sublingual Tablets in allergic rhinitis (AR), allergic conjunctivitis (AC) and house dust mite allergy (4 arms), sponsored by Lofarma S.p.A. Primary endpoint: Change in mean Lebel's Symptoms Score at final TNPT versus baseline. Started May 2018; status: completed.
02
Drugs
LAIS Mites Sublingual Tablets
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)house dust mite allergy
Beyond the preview
Go deeper on 2017-005079-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005079-21.